4-氟-3-(羟甲基)苯基硼酸 | 481681-02-1

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-3-(羟甲基)苯基硼酸
• 中文别名: 4-氟-3-羟甲基苯硼酸
• 英文名称: (4-fluoro-3-(hydroxymethyl)phenyl)boronic acid
• 英文别名: [4-Fluoro-3-(Hydroxymethyl)Phenyl]Boronic Acid
• CAS: 481681-02-1
• 化学式: C₇H₈BFO₃
• mdl: MFCD08235075
• 分子量: 169.948
• InChiKey: PWMOQHMTXJYUGE-UHFFFAOYSA-N

物化性质

• 熔点：
  124-126
• 沸点：
  365.8±52.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.94
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  请保持冷敷。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Fluoro-3-(hydroxymethyl)phenylboronic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Fluoro-3-(hydroxymethyl)phenylboronic acid
Ingredient name:
CAS number: 481681-02-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H8BFO3
Molecular weight: 169.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氟-3-(羟甲基)苯基硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 5%-palladium/activated carbon potassium phosphate 、 氢气 、 sodium hydride 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 0.42h， 生成 3-[4-fluoro-3-(2-methoxymethyl)-phenyl]-1-trityl-1H-indazol-5-ylamine
  参考文献：
  名称：

  WO2008/153858

  摘要：

  公开号：
• 作为产物：
  描述：

  5-溴-2-氟苯甲醛 在 sodium tetrahydroborate 、 正丁基锂 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 为溶剂， 反应 5.67h， 生成 4-氟-3-(羟甲基)苯基硼酸
  参考文献：
  名称：

  [EN] PHOSPHONATE CONJUGATES AND USES THEREOF
  [FR] CONJUGUÉS DE PHOSPHONATE ET LEURS UTILISATIONS

  摘要：

  磷酸酯共轭物，最好是双磷酸酯共轭物；抑制Ron受体酪氨酸激酶的方法以及利用所提供的磷酸酯共轭物治疗因癌症或其他疾病导致的骨破坏的方法。

  公开号：

  WO2020150307A1
• 作为试剂：
  描述：

  、 {2-Fluoro-5-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-methanol 以 4-氟-3-(羟甲基)苯基硼酸 为溶剂， 生成 2-Fluoro-5-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-benzaldehyde
  参考文献：
  名称：

  Hetero-bridge substituted 8-arylquinoline pde4 inhibitors

  摘要：

  8-芳基喹啉中，位于8位的芳基基团包含一个与苯、5或6成员杂环芳基或融合的双环杂环芳基群之间的一个或两个原子桥，且至少有一个桥中的原子不是碳，它们是PDE4抑制剂。

  公开号：

  US20050245513A1

文献信息

• [EN] ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLES SUBSTITUÉS ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015089809A1

  公开（公告）日：2015-06-25

  The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  本发明涉及一种由公式I表示的化合物：以及它们的药用可接受盐。公式I的化合物是G蛋白偶联受体40（GPR40）的激动剂，可用于治疗、预防和抑制由G蛋白偶联受体40介导的疾病。本发明的化合物可用于治疗2型糖尿病，以及通常与该疾病相关的状况，包括肥胖和脂质紊乱，如混合型或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症。
• [EN] ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE SUBSTITUÉ ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015095256A1

  公开（公告）日：2015-06-25

  The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  本发明涉及一种由公式（I）表示的化合物：以及药学上可接受的盐。公式I的化合物是G蛋白偶联受体40（GPR40）的激动剂，并且可能对由G蛋白偶联受体40介导的疾病的治疗、预防和抑制有用。本发明的化合物可能在治疗2型糖尿病，以及通常与该疾病相关的状况，包括肥胖和脂质紊乱，如混合型或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症中有用。
• [EN] 8-(BIARYL) QUINOLINE PDE4 INHIBITORS<br/>[FR] INHIBITEURS DE PDE4 8-(BIARYLE)QUINOLINES
  申请人：MERCK FROSST CANADA INC

  公开号：WO2004000814A1

  公开（公告）日：2003-12-31

  8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues.In another aspect, the present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and cognition enhancing amount of a phosphodiesterase-4 inhibitor.

  8-(联苯基)喹啉类化合物，其中在8位的联苯基与喹啉基团呈间位关系，是磷酸二酯酶4抑制剂，在治疗哮喘、慢性支气管炎、慢性阻塞性肺疾病、嗜酸性肉芽肿、牛皮癣和其他良性或恶性增生性皮肤疾病、内毒素休克、马蹄炎、马胃肠炎、脓毒性休克、溃疡性结肠炎、克罗恩病、心肌和脑再灌注损伤、炎症性关节炎、慢性肾小球肾炎、特应性皮炎、荨麻疹、成人呼吸窘迫综合征、动物慢性阻塞性肺疾病、尿崩症、过敏性鼻炎、过敏性结膜炎、春季结膜炎、动脉再狭窄、动脉粥样硬化、动脉粥样硬化、神经源性炎症、疼痛、咳嗽、类风湿性关节炎、强直性脊柱炎、移植排斥反应、移植物抗宿主病、胃酸过多分泌、细菌、真菌诱导的败血症、病毒诱导的败血症、真菌诱导的脓毒性休克、病毒诱导的脓毒性休克、炎症介导的慢性组织退行性变、细胞因子介导的慢性组织退行性变、骨关节炎、癌症、虚弱、肌肉消耗、抑郁症、记忆障碍、肿瘤生长或癌细胞侵袭正常组织。另一方面，本发明涉及一种增强健康受试者认知能力的方法，包括给予安全的增强认知量的磷酸二酯酶4抑制剂。具体而言，本发明涉及一种增强健康受试者记忆、学习、保留、回忆、意识和判断能力的方法，包括给予安全且增强认知量的磷酸二酯酶4抑制剂。
• 基于介孔氧化硅纳米粒子的控释系统及其制 备方法
  申请人：华东理工大学

  公开号：CN105169398B

  公开（公告）日：2020-08-18

  本发明涉及一种基于介孔氧化硅纳米粒子的控制释放系统及其制备方法，具体涉及基于介孔氧化硅的可用于控制释放的纳米粒子、含有该纳米粒子的控制释放系统、该纳米粒子的制备方法及试剂盒。本发明的纳米粒子含有经苯基硼酸酯功能化的介孔氧化硅纳米粒子和可与苯基硼酸酯结合的表面功能化的纳米粒子堵孔剂。在无底物存在下，本发明的纳米氧化硅体系可达到“零提前释放”；当加入底物后，被纳米粒子封堵的介孔孔道被打开，从而实现内载物的控制释放。本发明方法材料合成简单，结构可调，可以实现对不同底物、不同浓度的响应。
• Achieving C(sp²)–C(sp³) Coupling with BCP-F₂ Building Blocks via Barluenga Coupling: A Comparative Approach
  作者：Xiaoshen Ma、Charles S. Yeung

  DOI：10.1021/acs.joc.1c01370

  日期：2021.8.6

  We report our efforts toward achieving C(sp2)–C(sp3) coupling reactions with 2,2-difluorobicyclo[1.1.1]pentane (BCP-F2) building blocks. By comparing the reactivities of matching pairs of bicyclo[1.1.1]pentane (BCP) and BCP-F2 analogues, we discovered that the Barluenga coupling reaction was the only cross-coupling protocol that translated well between the two structural motifs in contrast to other

  我们报告了我们为实现 C(sp 2 )–C(sp 3 ) 偶联反应与 2,2-二氟双环[1.1.1] 戊烷 (BCP-F 2 ) 构建单元所做的努力。通过比较双环 [1.1.1] 戊烷 (BCP) 和 BCP-F 2类似物匹配对的反应性，我们发现 Barluenga 偶联反应是唯一一种在两种结构基序之间转换良好的交叉偶联方案，与其他报告的协议。在该化学中，带有甲苯磺酰腙官能团的 BCP-F 2与芳基硼酸交叉偶联。这些结果进一步扩展了 BCP-F 2构建块的范围，用于有机化学和药物化学的潜在应用。